Although the recent Myriad and Monsanto decisions purport to be closely tied to their facts, the Court’s reasoning will affect industry players well outside the realms of human genes and genetically modified seeds. Myriad could upset established patenting strategies for technologies as diverse as therapeutic proteins, stem cells, and herbal extracts. Monsanto suggests that patent holders should reconsider contract provisions for replicable technologies like plasmids, genetically modified organisms, and cell lines.
Ropes & Gray Speakers
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.